经皮双针囊内注射类固醇治疗小儿孤立性骨囊肿

目的探讨经皮双针囊内注射类固醇治疗小儿孤立性骨囊肿的疗效. 方法 1996年1月～2004年1月,对28例小儿孤立性骨囊肿,在X线透视下,将2根细的骨穿针或腰穿针分别自囊腔顶部和底部刺入骨囊肿内,抽去囊液,冲洗囊腔后注入类固醇. 结果 27例随访10～62个月,平均28个月,无并发症发生.根据Chigira等X线骨囊肿愈合评价标准,Ⅳ级20例,Ⅲ级5例,Ⅱ例1例,Ⅰ级1例,治愈率92.6%(25/27).25例骨囊腔愈合时间3～10个月,平均4.5个月. 结论经皮双针囊腔内注射类固醇适合于小儿孤立性骨囊肿,简单,安全,治愈率高.     

椎弓根固定结合椎体成形术治疗胸腰椎爆裂骨折

目的探讨椎弓根固定结合经椎弓根椎体内植骨行椎体成形术治疗胸腰椎爆裂骨折的疗效。方法采用椎管环形减压、短节段椎弓根螺钉系统固定结合经椎弓根椎体内植骨治疗胸腰椎爆裂骨折116例,其中93例获得随访。术前及术后随访行X线和CT检查,测量伤椎椎体中央高度值,比较植骨后椎体高度的恢复程度,同时观察植骨融合情况。采用配对t检验方法进行统计学分析。结果93例患者术后平均随访24.2个月,90%以上患者伤椎椎体高度恢复并维持良好,无塌陷。伤椎椎体中央高度值犤T12(3.14±0.41)cm,L1(3.33±0.34)cm犦与正常值犤(T12(3.26±0.38)cm,L1(3.47±0.61)cm)犦比较,差异无显著性意义(P>0.05)。未出现植骨操作引起的神经血管并发症。CT显示椎体内植骨块边缘模糊,融合良好,植骨块无吸收现象。结论后路椎管环形减压及内固定时,经伤椎椎弓根进行椎体内植骨行椎体成形术可恢复伤椎椎体高度,重建前、中柱的稳定性,预防术后椎体塌陷的发生。     

Warping of cross sections in the torsion of long bones with internal fracture fixation plates

Torsion of noncircular beams results in warping of each cross section. When noncircular cross sections are constrained to remain plane, the resulting shear stress distribution is different from what Saint Venant torsion (with warping) would predict. This has practical implications to the stress analysis of plated long bones subjected to torsional loadings. Analyses in which warping is not allowed predict incorrect stress fields in the plate and bone and overpredict the amount of stress shielding associated with fracture plate fixation.     

双头加压螺纹钉贴股骨距内固定治疗股骨颈骨折

在Ｘ光电视下采用双头加压螺纹钉贴股骨距内固定治疗新鲜股骨颈骨折４２例，随访平均２．５年，其中１６例随访３年以上，骨折愈合率９５．２％，骨折不愈合并股骨头缺血性坏死率４．７６％。认为加压螺纹钉贴股骨距内固定可使钉的受力由较大剪应力变为较大轴向力承受，减少骨折处的剪应力，并加压于骨折端能促进骨折愈合。具有操作简单、进钉准确、创伤小、固定牢靠、并发症少等优点。     

Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal,bone-active drug ipriflavone

Hormone replacement therapy is the optimal therapeutic choice for postmenopausal syndrome. While low doses of estrogens (0.3 mg/day of conjugated estrogens) can counteract neurovegetative menopausal symptoms, higher doses (0.625 mg/day of conjugated estrogens) are required to prevent bone loss in postmenopausal women. Experimental and clinical studies have shown that ipriflavone, a non-hormonal isoflavone derivative, is effective in the prevention and treatment of postmenopausal osteoporosis. The aim of the present investigation was to evaluate the efficacy and toler-ability of ipriflavone and very low doses of equine conjugated estrogens on bone loss in early postmenopausal women. Eighty-three healthy postmenopausal women (50.3±0.7 years) were enrolled for this 1-year multicenter study. All subjects were randomly allocated to receive: double placebo (n=24; group A), placebo plus conjugated equine estrogens 0.30 mg/day (n=31; group B) or conjugated equine estrogens 0.30 mg/day plus oral ipriflavone 200 mg tris in die at meals (n=28; group C), according to a double-masked design. Among women who completed the treatment period (valid completers), those of group A showed a progressive decrease in forearm bone density (FBD; measured by dual photon absorptiometry) that reached 1.7% after 12 months. The women in group B maintained their FBD in the first 6 months of treatment but, at the end of the study, showed a bone loss of 1.4% compared with basal values. By contrast, women in group C showed a significant increase in FBD after 1 year of treatment (+5.6%;p<0.01). Bothvalid completers andintention to treat analyses revealed a significant difference (p<0.05) between group A and group C over the study period. None of the treatments produced significant changes of biochemical markers of bone turnover, while hot flushes and other climacteric symptoms were significantly reduced after the sixth month of treatment in women receiving estrogens. Adverse events were generally mild, and did not differ among the groups. The results of this study suggest that low doses of estrogens combined with ipriflavone could represent a new therapeutic approach to the treatment of the postmenopausal syndrome.     

牛骨形成蛋白在骨不连中的临床应用

应用牛骨形成蛋白（ｂｏｖｉｎｅＢｏｎｅＭｏｒｐｈｏｇｅｎｅｔｉｃＰｒｏｔｅｉｎ简称ｂ－ＢＭＰ）成功的治愈１３例骨不连病人。经过１３个月～２９个月随访观察，效果较好。本组病人术前平均已做过１．５次手术。１３例病人中，有１２例被１次治愈。１例病人再次行内固定加用牛骨形成蛋白的植入也被治愈。骨形成蛋白的应用方式，采用同锻石膏复合后植入骨不连处。平均每个病人植入１００ｍｇＢＭＰ，１３例病人平均治愈时间为４．７个月。术后没有任何并发症。     

Ridge number density: A new parameter for in vivo bone structure analysis

An advanced analysis of the mechanical properties of bone should include information about the microarchitecture of cancellous bone in addition to its density. It has recently been shown that high-resolution quantitative computed tomography and magnetic resonance imaging have the potential to assess such information in a noninvasive way in patients. Both techniques, however, lack sufficient spatial resolution to image the individual trabeculae with true precision. In this work, a new parameter, Ridge number density (RND), is introduced. RND is a measure for the trabecular number, which can be extracted directly from high-resolution three-dimensional (3D) images of patients. We applied the RND technique to a test group of nine healthy, postmenopausal women measured repetitively with a high-resolution 3D peripheral quantitative computed tomography (3D-pQCT) system with 165 × 165 × 165 μm³ voxel size. Simultaneously with the RND determination, the trabecular bone density (TBD) was also assessed in the same volume of interest. The examination site was the distal radius. The intersubject variability of the measured test group was 10.5% for RND and 26.3% for TBD. The root mean square error between first and second examinations (midterm reproducibility) was 1.6% and 1.1%, respectively. RND is determined independently from TBD and pertains to the structure of the cancellous bone. As such, it might add crucial information in cases where bone mass or bone density measurements alone give ambigous results.     

胎骨移植治疗骨肿瘤缺损：附10例报告

近3年来，用制备的胎骨充填良性骨肿瘤及病样病变术后骨缺损，经观察10例效果良好。胎骨因其自身组织学和生理学特点，具有抗原性小、诱导成骨活性高，利于“爬行各代”等优点。而且来源丰富、采制简单、储存容易、费用低度，是一种良好的植骨材料，特别适于儿童及年老体弱患者自身取骨困难的骨缺损植骨需要。但其为异体骨，有一定免疫原性，抗支撑强度略差，应注意严格无菌操作、消除免疫原性、配合使用内、外固定等措施。     

鼻咽癌骨转移核素显像分析

目的：探讨鼻咽癌骨转移喷射有显像的特点及规律。方法：选择６１例鼻咽癌患者做全身骨核素显像。结果：６１例鼻咽癌患者中有３９例骨显像异常，结合临床及Ｘ线诊断为骨转移，骨转移的发生率为６３．９％，临床Ⅰ、Ⅱ、Ⅲ、Ⅳ期的发生率分别是０、４１．７％、５７．７％、８６．４％。３９例骨转移患者中３６例多发病灶（占９２．３％），３例为单发病灶（占７．７％）。骨转移的部位以脊柱为多见，其余依次为胸部、骨盆、肢体和颅